Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor, Idelalisib (GS-1101), in IgM-Associated AL Amyloid

NCT02590588 is registered in ClinicalTrials.gov with John Mark Sloan as lead sponsor.

NCT NCT02590588
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02590588 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor, Idelalisib (GS-1101), in IgM-Associated AL Amyloid
Lead sponsor
John Mark Sloan
Phase
Phase 2
Overall status
Terminated
Start date
January 31, 2016
Completion date
March 27, 2017
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

amyloidosis